EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043

Simon E Koele iD, Norbert Heinrich, Veronique R De Jager, Julia Dreisbach iD, Patrick P J Phillips, Petra Gross-Demel, Rodney Dawson, Kim Narunsky, Leticia M Wildner, Timothy D Mchugh, Lindsey H M Te Brake, Andreas H Diacon und 3 weitere

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Simon E Koele und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Antitubercular Agents, Tuberculosis, Pulmonary, Thiazines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PanACEA-TB consortium, Veni project, German Ministry for Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

BTZ-043 is a first-in-class benzothiazinone for the treatment of TB with demonstrated early bactericidal activity. BTZ-043 is metabolized into two major metabolites: M1 and M2. The aim of this study was to characterize the pharmacokinetics (PK) and early exposure–response (pharmacokinetic/pharmacodynamic, PK/PD) relationship for BTZ-043.

Methods

A population PK/PD model for BTZ-043 and its metabolites was developed using data from a sequential Phase 1b/2a, randomized, controlled clinical trial in participants with pulmonary TB. BTZ-043 was administered in daily doses ranging from 250 to 1750 mg over 14 days. The decrease in bacterial load was determined by culture of sputum samples to quantify cfu on solid medium, and time to positivity in liquid medium.

Results

In total, 77 participants received the experimental treatment. PK were best described by two-compartment disposition models for BTZ-043 and M2, and a one-compartment disposition model for M1. When given without food, the bioavailability was 54% (95% CI: 43%–65%) lower than with food. The decrease in bacterial load was described by a bilinear model with estimated node at 48 h. Participants in the highest dose group in Stage 2 (1000 mg) had a 2-fold faster decrease in mycobacterial load during the initial 2 days compared with participants in the lowest dose group (250 mg), driven by an Emax relationship to the BTZ-043total exposure (BTZ-043 + M2).

Conclusions

We characterized the population PK/PD of BTZ-043 in trial participants with pulmonary TB. An exposure–response relationship was only apparent for the first 2 days on treatment, indicating the need for further dose-finding studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsTuberculosis, PulmonaryThiazinesHumansMaleAdultFemaleMiddle AgedSputumYoung AdultBacterial LoadAgedMycobacterium tuberculosisTreatment OutcomeAdolescent

Substanzen

Antitubercular AgentsThiazines

Autor:innen und Institutionen

  • Department of Pharmacy, Radboud Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU, Munich, Germany.
  • German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.
  • TASK, Cape Town, South Africa.
  • UCSF Center for Tuberculosis, University of California San Francisco, San Francisco, USA.

ORCID-Profile: Simon E Koele, Julia Dreisbach, Michael Hoelscher

Förderung

  • PanACEA-TB consortium
  • Veni project
  • German Ministry for Education and Research
  • German Center for Infection Research
  • InfectControl
  • Bavarian Ministry for Science and the Arts
  • Swiss State Secretariat for Education, Research, and Innovation
  • Dutch Research Council

Zitieren

APA

Koele, S. E., Heinrich, N., De Jager, V. R., Dreisbach, J., Phillips, P. P. J., Gross-Demel, P., Dawson, R., Narunsky, K., Wildner, L. M., Mchugh, T. D., Te Brake, L. H. M., Diacon, A. H., Aarnoutse, R. E., Hoelscher, M., & Svensson, E. M. (2025). Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf076

Vancouver

Koele SE, Heinrich N, De Jager VR, Dreisbach J, Phillips PPJ, Gross-Demel P, et al. Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf076

BibTeX
@article{Koele2025,
  author = {Koele, Simon E and Heinrich, Norbert and De Jager, Veronique R and Dreisbach, Julia and Phillips, Patrick P J and Gross-Demel, Petra and Dawson, Rodney and Narunsky, Kim and Wildner, Leticia M and Mchugh, Timothy D and Te Brake, Lindsey H M and Diacon, Andreas H and Aarnoutse, Rob E and Hoelscher, Michael and Svensson, Elin M},
  title = {Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf076}
}
Kostenlos starten →